Prospective clinical study, where patients are receiving or the study drug or an inactive drug called placebo wihtout knowing which of the two drugs is taken, even the Investigator is aware of the therapy taken by the patients. Patients are assigned to a specific treatment according to a randomization list. The study is performed to assess the effects and tolerability of K(D)PT in ulcerative colitis.

• Conditions: mild to moderate ulcerative colitis; MedDRA version: 14.1Level: SOCClassification code 10017947Term: Gastrointestinal disordersSystem Organ Class: 10017947 - Gastrointestinal disorders; Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

• Registration Number: EUCTR2011-002462-20-IT
• Lead Sponsor: DR. AUGUST WOLFF GMBH & CO. KG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03-08
• Last Update Posted: 23 September 2013

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

.written informed consent. .males or females, aged 18 to 70 years (inclusive). .Females of childbearing potential must have a negative urine pregnancy test at screening and must agree to use adequate contraception until week 12. .Females of non-child bearing potential should be postmenopausal for >1 year or permanently sterilised. .Male patients must agree to use adequate contraception. .BMI =19 and =30 kg/m2. .Mild to moderately active UC proven by endoscopy and defined as a CAI of 6 to 12. .Pre-treatment of active ulcerative colitis with a stable dose of oral mesalazine, sulphasalazine or olsalazine for >4 weeks and/or azathioprine or 6-mercaptopurin for >3 months, or oral corticosteroids of =20 mg oral prednisolone or equivalent for >2 weeks.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 140
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

1.Pregnant, planning to become pregnant during the study, or breast feeding females. 2.Previous participation in any clinical study with K(D)PT. 3.Crohn’s disease. 4.Treatment-naive. 5.Infectious diarrhoea within 14 days before or during the treatment period. 6.Indeterminate colitis. 7.Significantly impaired liver, renal, pulmonary or cardiovascular function. 8.Use of antibiotics within 4 weeks before or during the treatment period. 9.Use of E. coli Nissle within 4 weeks before or during the treatment period. 10.Previous use of cyclosporine, anti-TNF therapy (e.g. infliximab) or tacrolimus at any time. 11.Any rectal therapy four weeks before or during the treatment period. 12.Use of corticosteroids >20 mg oral prednisolone or equivalent. 13.Use of methotrexate within 3 months before or during the treatment period. 14.Use of anti-diarrhoeal drugs within 2 weeks before or during the treatment period. 15.Effective anti-coagulation therapy (e.g. Marcumar) or severe grade coagulation defects. 16.Any clinically relevant abnormal findings at screening, vital signs or ECG which, in the opinion of the investigator, may put the patient at risk because of his or her participation in the study. 17.History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or could influence the results, or the patient’s ability to participate in the study. 18.History of or current alcohol or drug abuse, as judged by the investigator. 19.Participation in another investigational drug study within 3 months before first administration of study medication. 20.Donation of blood within 3 months, or donation of plasma within 2 weeks, before the first administration of study medication. 21.Proctitis (=5 cm). 22.QTcF >450 ms or <350 ms or QT >500 ms or other relevant ECG abnormality as judged by the investigator. 23.History of pathological skin condition. 24.Known intolerance to methylparaben or propylparaben. 25.Known intolerance to any other excipient of the investigational medicinal product (IMP). 26.Positive history of hepatitis B and/or C and/or history of human immunodeficiency virus (HIV). 27.Planned surgery or hospitalisation during the study. 28.Patients who, in the opinion of the investigator, should not participate in the study. 29.Patients unable to understand informed consent.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified